Trials that use: Fisher exact test
New to this method? Read the tutorial →
5,849 results
- Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00730522).
- Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis: primary endpoint results, effect estimate…
- Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD): Complete Statistical AnalysisIndependent statistical analysis of Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule): primary endpoint results, effect estimate with confidence…
- Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second…
- Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®: primary endpoint results, effect estimate with…
- Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of GSK’s Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01147068).
- Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine: primary endpoint results, effect…
- Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea: primary endpoint results, effect estimate with confidence…
- Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals’ 10-valent Pneumococcal Conjugate Vaccine.: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity Study of GSK Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years: primary endpoint results, effect estimate with…
- Safety and Immunogenicity Study of Na-GST-1 With or Without CpG: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of Na-GST-1 With or Without CpG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02143518).
- Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04074928).
- Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Performance Study of the Harpoon Mitral Valve Repair System: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance Study of the Harpoon Mitral Valve Repair System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016): primary endpoint results, effect estimate with…
- Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00845650).
- Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals’ IPV Vaccine (PoliorixTM) in Toddlers: Complete Statistical AnalysisIndependent statistical analysis of Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…